Merck's Vioxx Gains First-Line Juvenile Rheumatoid Arthritis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval marks first pediatric indication for COX-2 inhibitor class. Pfizer's competing COX-2s Celebrex and Bextra are not being developed for JRA; the Vioxx JRA approval is based on a single non-inferiority trial.